Return to search

Kanaph Therapeutics scores $21m Series B

Kanaph Therapeutics, a South Korea-based biotech company in oncology, auto-immune, and eye diseases with large molecules and small molecules, has raised $21 million in Series B funding.

Kanaph Therapeutics, a South Korea-based biotech company in oncology, auto-immune, and eye diseases with large molecules and small molecules, has raised $21 million in Series B funding. The investors included GC Pharma, Kolon Investment and Timefolio Asset Management.

Source: Press Release